Sight Sciences Inc (SGHT) Prévision du cours des actions

Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company is headquartered in Menlo Park, California and currently employs 186 full-time employees. The company went IPO on 2021-07-15. The firm is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The firm operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.